恩替卡韦联合复方甘草酸苷治疗48例肝癌患者．的疗效观察

目的探讨恩替卡韦联合复方甘草酸苷治疗原发性肝癌的临床治疗效果。方法选取2009年6月～2012年5月在我院消化内科住院的肝癌患者48例，随机分为试验组和对照组各24例，两组均行TACE治疗，同时均在术后1周予常规保肝治疗，其中试验组在术前1周予恩替卡韦联合复方甘草酸苷治疗，比较两组患者治疗前后ALT、AST、TBil、HBV—DNA的变化情况。结果两组术后出现不同程度肝功能损伤，术后1周，两组实验室检查表现为ALT、AST、TBil均较术前明显升高，差异有统计学意义（P〈0．05）。但试验组ALT、AST、TBil升高程度均低于对照组，差异有统计学意义（P〈0．05）。术后2周，试验组AST、TBil、HBV—DNA均较术前明最降低，且试验组明显低于对照组．差异有统计学意义（P〈0．05）。但ALT术后2周与术前比较未见明显差异，对照组HBV—DNA水平治疗前后也变化不明显。结论恩替卡韦联合复方甘草酸苷治疗原发性肝癌疗效确切，可以明显改善患者的肝功能．值得广泛推广和应用。

The efficacy of enticavir with compound glycyrrhizin for forty-eight liver cancer patients

Objective To explore the efficacy of entecavir with compound glycyrrhizin for the hepatitis B virus （HBV） surface antigen （HBsAg）-positive primary hepatoeellular carcinoma （HCC） after TACE. Methods Forty-eight cases of liver cancer were divided into two groups. 24 patients were given by enticavir （0.5 mg / d） with compound gly cyrrhizin for intravenous injection （80 mg/d） before the TACE; the other 24 patients of control group were given the TACE treatment only. All patients were given the conventional liver treatment hepatoprotection therapy. Liver function and the change of serum HBV-DNA before and after TACE were observed. Results At after TACE treatment one week, the increasing of ALT, AST, TBil in two groups,and the enticavir compound with glycyrrhizin was lower than the control group （P 〈 0.05）; after TECA treatment 2 weeks, the recovery of the liver damage of the experimental group was significantly better than the control group （P 〈 0.05）; At one week after the operation, serum HBV-DNA levels in the group of enticavir with compound glyeyrrbizin decreased obviously, but serum HBV-DNA had no obvious change. Conclusion Entecavir with compound glyeyrrhizin can obviously alleviate the degree of liver function damage after TACE, and is beneficial for rescovery of liver function.